TTUHSC School of Pharmacy
HomeSOPFaculty & Staff Directory

Faculty & Staff Details

Profile for Mary Klein, Pharm.D., BCACP

Mary Klein

Mary Klein, Pharm.D., BCACP

  • Assistant Professor of Pharmacy Practice
Office Phone: 325-696-0445
Mail Address: 1718 Pine St
Abilene TX 79601-3044


Dr. Klein is involved primarily with laboratory teaching and maintains a practice site at Presbyterian Medical Mission of Abilene. Dr. Klein teaches in Clinical Immunizations and Administration, Patient Assessment, and Pharmaceutical Care Lab, in addition to precepting the Ambulatory Clinical Skills and the Primary Care rotations. Dr. Klein received her Bachelor of Science degree in Biology from Texas Tech University in 2003 and Doctor of Pharmacy from the TTUHSC School of Pharmacy in 2007. She then completed a community and ambulatory care pharmacy practice (PGY1) residency at the University of Texas at Austin/Scott and White Memorial Hospital, Health Plan, and Clinics in Temple and Georgetown, Texas. Her practice interests include family medicine, endocrinology, primary care, and medical missions. Research interesting including diabetes clinical outcomes research and educational design.

Selected Publications:

  • Ochoa PS, Terrell B, Vega JA, Lu C, Klein MS, . Identification of Previously Undiagnosed Diabetes and Prediabetes in the Inpatient Setting Using Risk Factor and Hemoglobin A1C Screening. Annals of Pharmacotherapy 2014.
  • Klein MS. Achieving Cholesterol Goals with Low-Cost 3-hydroxy-3- methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors in an Indigent Diabetic Population. JHPR 2014.
  • Horton NA, Payne KD, Frost J, Wise S, Klein MS, Epps JM, . A standardized patient counseling rubric for a pharmaceutical care and communications course. Am J Pharm Educ 2013;77:152.
  • Minze MG, Klein MS, Terrell B. Saxagliptin-metformin in fixed combination for the treatment of type 2 diabetes in adults. Clin Med Insights Endocrinol Diabetes. 2013;6:15-24.
  • Minze MG, Klein MS, Wise S. Once Weekly Exenatide: An Extended Duration Glucagon-Like Peptide Agonist for the Treatment of Type 2 Diabetes Mellitus. Pharmacotherapy 2013;33:627-38.